Plain-English translation of NCT05794971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new combination approach for colorectal cancer that has spread to the liver and is no longer responding to standard chemotherapy. The combination uses , an oral medication taken by mouth, together with a special type of chemotherapy called irinotecan drug-eluting beads, which are delivered directly into the liver tumors through a minimally invasive procedure. The goal is to see if this two-pronged approach can help patients whose cancer has already failed two rounds of earlier treatments.
People whose colorectal cancer has spread to the liver and stopped responding to standard chemotherapy have very few good options left. This trial exists to see whether combining this medication with a targeted delivery method can offer better results and give patients hope when other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive as an oral medication (taken by mouth) combined with a procedure where irinotecan-coated beads are delivered directly into your liver tumors to attack the cancer where it lives. The trial will involve regular visits to the hospital or clinic for monitoring, blood tests, and imaging scans to see how well the treatment is working. Your medical team will closely watch for side effects and adjust your care as needed throughout your participation.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China